Apollomics, Inc.
NASDAQ:APLMBiotechnology
Healthcare
$17.84 +34.72%
+$6.03 today
- Market cap
- $52.00M
- Beta
- 1.45
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$25.98
52W Low $3.66High $42.12
Volume 0.02M
Average 0.02M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$10.37M
FY 2025 · Annual
Investing Cash Flow
$218,000.00
FY 2025 · Annual
-96.4% YoYFinancing Cash Flow
$3.68M
FY 2025 · Annual
+685.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (94.8M) | (240.81M) | (172.59M) | (53.6M) | (10.94M) |
| Depreciation & Amortization | 681K | 775K | 669K | 361K | 255K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.12M | 3.58M | 12.69M | 10.93M | (979K) |
| Change in Working Capital | 2.64M | 6.49M | (3.57M) | 1.04M | (380K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 2.64M | 6.49M | (3.57M) | 1.04M | (380K) |
| Other Non-Cash Items | 40.04M | 187.14M | 119.6M | 12.53M | 1.67M |
| Operating Cash Flow | (43.31M) | (42.82M) | (43.21M) | (28.74M) | (10.37M) |
| Capital Expenditures | (7.55M) | (367K) | (6K) | (24K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (103.79M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 71.95M | 29M | 20.49M | 5.76M | 0 |
| Other Investing Activities | (7.06M) | 420K | 884K | 246K | 218K |
| Investing Cash Flow | (38.95M) | 29.05M | 21.37M | 5.98M | 218K |
| Debt Repayment | (528K) | (593K) | 24.04M | 661K | 3.73M |
| Common Stock Issued | 141K | 392K | 85K | 0 | 7K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.26M) | (93K) | (2.9M) | (193K) | (65K) |
| Financing Cash Flow | (1.64M) | (294K) | 21.23M | 468K | 3.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 2K | (15K) |
| Net Change in Cash | (83.91M) | (14.07M) | (619K) | (22.29M) | (6.49M) |
| Free Cash Flow | (50.86M) | (43.19M) | (43.22M) | (28.77M) | (10.37M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$10.9M
+ D&A$255.0K
+ Stock-Based Comp-$979.0K
+ Deferred Tax$0
- Working Capital-$380.0K
+ Other Non-Cash$1.7M
= Operating Cash Flow-$10.4M
- Capex$0
= Free Cash Flow-$10.4M
Analysis
FY2025 free cash flow is -$10.4M. FCF conversion is 94.8% of net income. Operating cash flow was -$10.4M, with capex of $0. The largest bridge item is Other Non-Cash at $1.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| 4/A | 4/A filing | Sep 24, 2026 | |
| 4/A | 4/A filing | Sep 24, 2026 | |
| 4/A | 4/A filing | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
Does APLM generate free cash flow?
Apollomics, Inc. (APLM) generated -$10.37M of free cash flow in fiscal 2025.
How much operating cash flow does APLM produce?
Operating cash flow was -$10.37M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.